BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bio-PAT - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bio-PAT
X-ORIGINAL-URL:https://bio-pat.org
X-WR-CALDESC:Veranstaltungen für Bio-PAT
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20230925T170000
DTEND;TZID=Europe/Paris:20230925T180000
DTSTAMP:20260613T120149
CREATED:20230911T071836Z
LAST-MODIFIED:20230911T071838Z
UID:9818-1695661200-1695664800@bio-pat.org
SUMMARY:FyoniBio Webinar: Alone but not lonely
DESCRIPTION:FyoniBio Webinar: Alone but not lonely – Designing an outgrowth-promoting environment for single cell cloning \n\n\n\n\n\n\n\nJoin Vicky Goralczyk and Lena Tholen\, Directors of Cell Line and Bioprocess Development at FyoniBio GmbH\, for the live webinar: „Alone but not lonely: Designing an out-growth promoting environment for single cell cloning“ on Sept 25th 2023. FyoniBio is a Bio-PAT member. \n\n\n\nRegistration \n\n\n\n\n\n\n\nDoing things quickly has become a paradigm in biopharma development. Simultaneously\, in early development\, variability is required to extract the most data and increase chances of success. This leads to a demand in high-throughput\, automated techniques\, and highly skilled professionals. Risk taking and early adoption of new techniques is part of innovation to optimize workflows\, especially when projects are highly individual and cannot follow standard routines. In clone development\, this includes working with very different host cell lines\, customized protocols\, and unforeseen circumstances which needs adaptable processes and multifunctional devices. \n\n\n\nIn this webinar\, Dr. Vicky Goralczyk and Dr. Lena Thoring\, Directors of Cell Line Development and Bioprocess Development at FyoniBio GmbH\, will present data on how the CellCelector platform can effectively be used for cell line development\, host cell engineering\, and cell adaptation. They will also cover how it was successfully integrated into FyoniBio‘s platform for the development of biopharmaceutics for autologous and allogeneic cell therapies. \n\n\n\nKey learning objectives \n\n\n\n Learn how to identify key development and manufacturing challenges Gain insight into commercial scalability strategies for late-stage cell therapies Discover ways to drive innovation to accelerate the delivery of cell therapies to patients faster Learn how\, when and why to leverage state-of-the-art facilities Explore the importance of end-to-end supply chain management\n\n\n\nWho should attend? \n\n\n\n Researchers looking for monoclonality assurance and comprehensive documentation. Organizations looking to significantly decrease their overall cell line development workflow duration\n\n\n\nCertificate of attendanceAll webinar participants can request a certificate of attendance\, including a learning outcomes summary\, for continuing education purposes. \n\n\n\nPresenters\n\n\n\n\n\n\n\nLena Tholen\, PhDDirector Cell Line Development and Bioprocess DevelopmentFyoniBio GmbH \n\n\n\n\n\n\n\nVicky Goralczyk\, PhDDirector Cell Line Development and Bioprocess DevelopmentFyoniBio GmbH \n\n\n\n\n\n\n\nLawrence HowesSelectScience
URL:https://bio-pat.org/event/fyonibio-webinar-alone-but-not-lonely
LOCATION:Venue: Online
ATTACH;FMTTYPE=image/jpeg:https://bio-pat.org/wp-content/uploads/2023/09/FyoniBio-Webinar.jpg
END:VEVENT
END:VCALENDAR